What question did this study set out to answer?

The study aims to explore the capabilities and improvements of Affinity Selection Mass Spectrometry (AS-MS) in drug discovery processes.

February 2, 2026

Affinity selection mass spectrometry (AS-MS) as a tool to accelerate drug discovery efforts

Key Points

The study aims to explore the capabilities and improvements of Affinity Selection Mass Spectrometry (AS-MS) in drug discovery processes.
Describes AS-MS as a biophysical binding assay that eliminates the need for labels.
Focuses on detecting molecular binders from large ligand pools based on molecular weight.
Proposes improvements in separation times and equilibrium conditions for enhanced results.
AS-MS shows potential for faster identification of active compounds in drug development.
Improvements in SAR could lead to shorter project cycles in drug discovery.

Abstract

AS-MS is a unique biophysical binding assay that does not rely on labels and can specifically detect binders from large pools of potential ligands based on molecular weight. There is still significant room for growth in areas of impact that will be driven by decreases in separation time and a move toward equilibrium conditions during separation. Increased use for driving rapid structure-activity relationships (SAR) has potential to decrease project cycle times in lead identification and optimization.

Affinity selection mass spectrometry (AS-MS) as a tool to accelerate drug discovery efforts

Key Points

Abstract

Cite This Study